UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2009

MEDICINOVA, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-33185**	**33-0927979**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

4350 La Jolla Village Drive, Suite 950
San Diego, CA 92122
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (858) 373-1500

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Representatives of MediciNova, Inc. (the "Registrant") will be attending the 27th Annual JPMorgan Healthcare Conference commencing January 12, 2009. A copy of the slide presentation to be used by the Registrant at investor meetings during this conference is attached hereto as Exhibit 99.1 to this Current Report.

The information in this Current Report, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed "filed" for any purpose, including for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing to this Current Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit	Description
99.1	Slide presentation of the Registrant

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICINOVA, INC.

Dated: January 12, 2009

By: /s/ Shintaro Asako
Shintaro Asako
Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit	Description
99.1	Slide presentation of the Registrant

Exhibit 99.1

Accelerating the global development and commercialization of innovative pharmaceuticals

Forward-Looking Statements

Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding MediciNova's clinical trials supporting safety and efficacy of product candidates and the potential novelty of such product candidates as treatments for disease, plans and objectives for clinical trials and product development, strategies, future performance, financial condition, liquidity and capital resources. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "would," or similar expressions. Actual results or events may differ materially from those expressed or implied in any forward-looking statements due to various factors, including, without limitation, the risks and uncertainties inherent in clinical trials and product development and commercialization, such as the uncertainty in results of clinical trials for product candidates, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials and the timing, cost and design of future clinical trials and research activities; the timing of expected filings with the FDA; MediciNova's failure to execute strategic plans or strategies successfully; MediciNova's collaborations with third parties; the availability of funds to complete product development plans and MediciNova's ability to raise sufficient capital when needed; intellectual property or contract rights; and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including MediciNova's annual report on Form 10-K for the year ended December 31, 2007 and its subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

MEDICINOVA

Corporate Overview: MediciNova, Inc.

Development Company Focused on Differentiated Product Candidates

- Unique access to differentiated, potentially high value assets primarily from Japanese alliances

MNOV Headquarters: San Diego, CA

New Approaches to Treat Serious Medical Conditions:

- MN-221: IV Acute Exacerbations of Asthma candidate
  - Potential $500 M US opportunity for MediciNova
- MN-166: Oral Multiple Sclerosis candidate
  - In 2007, over $8.2B in worldwide MS therapeutic sales*

Key Financials:

- Dual listed company on Nasdaq GM and JASDAQ Securities Exchange in Hercules
- ~$19M Market Cap as of 12/31/08
- ~$47.5M Cash, Cash Equivalents and Marketable Securities as of 9/30/08

**Source: MedAdNews, July 2008*

MEDICINOVA

Business Model: Return On Investment

In-License:

- Product candidates with significant clinical or preclinical data

Conduct Proof-of-Concept Clinical Trials:

- Conduct Phase I and Phase II clinical trials to demonstrate efficacy of compound

Two Pathways Towards ROI After Phase II:

1. Continue internal development of compound towards commercialization
2. Seek partnership for further development of compound

MediciNova has focused its resources on its two prioritized product candidates, MN-221 and MN-166. Following completion of the Phase II trial of MN-166, MediciNova will not pursue further significant clinical development of MN-166 until a partnership is secured. In addition, MediciNova will pursue a variety of initiatives to monetize its remaining product candidates.

Acute Exacerbations of Asthma

Definition:

- Long-lasting and severe asthma episode that is not responsive to initial bronchodilator or corticosteroid therapy

Market Opportunity:

- Approximately 2 million emergency room visits in the US each year*
  - 500,000 hospitalizations in the US
- Approximately 4,000 deaths annually in the US*
- Potential $500 M market opportunity for MediciNova

Current Standard of Care (SOC):

- Beta agonists (all patients) inhaled or nebulized
- Corticosteroids (66-77% of patients) IV or oral

**Source: National Center for Health Statistics / CDC*

MEDICINOVA

MN-221: A New Approach to Treating Acute Exacerbations of Asthma

MN-221: A novel, highly selective β2-adrenergic receptor agonist

Three Potential Advantages over current therapy

1. Better delivery system (IV) = Better Bioavailability
2. Greater selectivity for β2 receptors in the lungs (better binding)
3. Partial agonist for β1 receptor in the heart

MEDICINOVA

Human β-Adrenergic Receptor Selectivity

Test Drug	β_1 IC_{50} (M)	β_2 IC_{50} (M)	β_2-Adrenoceptor Selectiv (IC_{50} for β_1 / IC_{50} for β_2)
Levalbuterol	7.40E-06	1.40E-06	5.3
Albuterol	9.40E-06	1.60E-06	5.9
Terbutaline	6.00E-05	6.50E-06	9.2
MN-221	**5.90E-06**	**1.40E-07**	**42.4**

MEDICINOVA

Effect on Heart rate: Combination of MN-221 & Albuterol in Dogs



MEDICINOVA

MN-221: Positive Phase IIa Data

MN-221-CL-004 Study Design

- Randomized, placebo-controlled, double-blind, dose escalation
- 23 subjects with mild-to-moderate stable asthma ($FEV_1 \geq 60\%$ predicted)
- Doses tested (all for 15 minutes):
  - 0.35 µg /min
  - 1.0 µg /min
  - 3.5 µg /min
  - 10 µg /min
  - 16 µg/min
  - 30 µg/min
  - 60 µg/min

MN-221-CL-005 Study Design

- Randomized, single-blind, placebo-controlled, dose rate escalation
- 17 subjects with moderate-to-severe stable asthma ($40\% \leq FEV_1 \leq 75\%$ predicted)
- Two doses tested:
  - 16 µg/min for 15 minutes followed by 8 µg/min for 105 minutes (2-hour infusion with a total dose of 1,080 µg) or placebo
  - 30 µg/min for 15 minutes followed by 15 µg/min for 45 minutes (1-hour infusion with a total dose of 1,125 µg) or placebo

MN-221-CL-004 and MN-221-CL-005 Safety Data:

No clinically significant cardiovascular, ECG or vital sign changes, or other safety concerns observed at any dose tested

MEDICINOVA

Mean Change in FEV $_1$
Study: MN-221-CL-004



	Placebo	0.35µg/min	1.0 µg/min	3.5µg/min	10µg/min	16µg/min	30µg/min	60µg/min
Mean Baseline:	77.83%	77.67%	76.78%	81.60%	74.66%	75.78%	78.07%	79.78%
At 15 Minutes:	77.54%	79.45%	80.06%	85.74%	82.02%	83.90%	89.65%	88.04%
Δ % Predicted:	-0.29%	1.78%	3.28%	4.14%	7.36%	8.12%	11.58%	8.26%

MEDICINOVA

Mean Change in FEV $_1$
Study: MN-221-CL-005



MEDICINOVA

Phase II Interim Data
Study: MN-221-CL-006



- These reviews included data from a total of 18 of 36 planned patients with severe, acute exacerbations of asthma treated in emergency departments.
- Decrease in the hospitalization rate from 50% to 10% with the addition of MN-221 (in10 subjects) to standardized care (in 8 subjects)
- Improvement in FEV_1 values generally appeared to be greater for patients receiving MN-221 in addition to standardized treatment
- No safety concerns with adding MN-221 to standardized care were identified in these reviews

MN-221: Next Steps

MN-221-CL-007:

A randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the safety and efficacy of MN-221 in patients with severe, acute exacerbations of asthma

- Approximately 35 clinical sites in North America, Australia and New Zealand
- Enroll approximately 200 patients
- Enrollment anticipated to begin in March 2009 for North American clinical sites (enrollment expected to complete after nine to twelve months)
- Doses: 1.2mg of MN-221 over one hour + Standardized Care
  Placebo + Standardized Care
- Primary efficacy endpoint will be improvement in FEV_1 (% predicted) at 5 hours

MEDICINOVA

MN-221 Development Plan



**Anticipated commencement and completion dates based on current projections*

If we are successful in completing the double-blind Phase IIb clinical trial, we plan to conduct a Phase III program. If we are successful in completing the Phase III program, we would then plan to file an NDA with the FDA to seek regulatory approval for MN-221.

Note: Development plans / timelines for MN-221 are subject to change

MEDICINOVA

Multiple Sclerosis

Definition:

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS), affecting approximately 500,000 people in the United States and 2 million people worldwide.

There is no cure for the disease.

Multiple Sclerosis Market:

Over $8.2 B worldwide sales in 2007*

Current Standard of Care:

- Beta interferons (Rebif, Avonex, Betaserone), Copaxone®, Tysabri®
- Administered either by intramuscular or subcutaneous injection or infusion

**Source: MedAdNews, July 2008*

MEDICINOVA

MN-166: A New Approach to Treating Multiple Sclerosis

MN-166:

- Anti-inflammatory and neuroprotective properties *in vitro* and *in vivo*
- Demonstrated effects on brain volume and lesion evolution to axonal damage
- Targets primarily chronic aspects of multiple sclerosis
- Oral administration

Mechanisms of Action:

- ✓ Stimulates Neurotrophic Growth Factor Release
- ✓ Inhibits nitric oxide and reactive oxygen species production
- ✓ Inhibits Th1 cytokine production (IFN-γ, TNF-α, IL-1β, IL-6)
- ✓ Pilot studies found reduced relapse rate and Th2 → Th1 cytokine shift
- ✓ Phosphodiesterase IV and Leukotriene inhibitor

MEDICINOVA

Current Clinical Studies: MN-166-CL-001

Placebo-controlled, randomized, double-blind Phase II study:

- Year 1 0, 10 mg tid, 20 mg tid
- Year 2 10 mg tid, 20 mg tid
- n ~ 100 MS patients/group @ 25 sites in Serbia, Ukraine, Belarus, Bulgaria and Romania

Key inclusion criteria:

- Males or females aged 18 to 55 years, with relapsing remitting (RR) and/or secondary progressive (SP) Multiple Sclerosis with continued relapses;
- A definite diagnosis of relapsing MS using the new International Committee recommendations (MacDonald Criteria);
- One MRI scan taken two weeks prior to treatment start using a standardized MRI protocol with at least one Gd-enhancing lesion;
- An EDSS score of 5.5 or less at the screening and baseline visits.

MN-166 Targets Primarily Chronic Aspects of MS

MN-166 Effects Outcomes Related to Disease Progression in RRMS Patients

Clinical and MRI Outcomes:

Indicative of Potential Neuroprotective Effect

1. Reduced Brain Volume Loss — ***P-Value: 0.030***
2. Reduced Conversion of Acute Lesions to Persistent Black Holes — ***P-Value: 0.011***
3. Sustained disability progression was significantly less likely (~50%) — ***P-Value: 0.026***

Acute Clinical Benefit:

- Prolong time to relapse (by 127 days.) — ***P-Value: 0.044***

MN-166 was very well tolerated in Phase II study:

- 89% (264 of 297) of subjects completed the first 12 months of the study
- 82.5% (245 of 297) of subjects completed the full 24 months of the study
- GI adverse effects as a group and depression were the only adverse events to occur more frequently in MN-166-treated than in placebo-treated subjects

MEDICINOVA

Chronic Efficacy Demonstrated: Effects on Brain Volume



Brain volume loss was significantly less (p=0.030) in patients rec per day of MN-166 for 24 months compared to the other treatme

MEDICINOVA

Reduction of Persistent Black Hole (PBH) Formation

Parameter	Treatment Groups		
	Placebo	30 mg/day	60 mg/day
Number Patients w. New Lesions at Month 2	72	64	56
Total Number New Lesions in all Patients	426	338	315
Total Number of Persistent Black Holes	98	58	47
Proportion of Lesions Evolving to PBH	0.23	0.17	0.14
p Value	-	**0.036**	**0.004**

- **New T1 gadolinium-enhancing or new T2 lesions were defined as NL in the first on-study MRI at month 2**
- **Lesions that were hypointense and inactive at month 10 were PBH**
- **Relative Risk (RR) of NL evolution to PBH was analyzed using a general linear model with the error term from the Poisson distribution**

MEDICINOVA

Sustained Disability Progression

	TREATMENT	
Time Period	**Placebo to Active (N=100)**	**Active Drug [30 mg (N=94), 60 mg (N=98)]**
2 Years	**21/100 (21%)**	**20/194 (10.4%)**

P-Value: 0.026

Disability Progression is defined as a sustained increase i
(increase in EDSS 1 maintained for four consecutive month

21

Acute Efficacy Demonstrated: Time to First Relapse



MEDICINOVA

MN-166: NEXT STEPS

Seek Partnership for Further Development:

MediciNova's strategic objective for MN-166 is to secure a partner to advance the clinical development of MN-166, and MediciNova is actively pursuing that objective

MEDICINOVA

Commercially-Attractive Diversified Portfolio



Key Financials

Dual Listing:

- MNOV (NasdaqGM), December 2006
- 4875 (Osaka Hercules), February 2005

Cash, Cash Equivalents and Marketable Securities as of 6/30/08 :

~$47.5 M as of 9/30/08

Market cap as of 12/31/08:

~$19M

Shares outstanding:

11.9 M

MEDICINOVA

Management Team with Global Experience



Leadership	Years Experience	Background
Yuichi Iwaki, MD, PhD CEO & President	33	Prof. USC, Formerly Prof. Pitt; Advisor to JAFCO, Tanabe
Richard Gammans, PhD, MBA Chief Development Officer	31	Incara, Indevus, BMS
Shintaro Asako, CPA Chief Financial Officer	10	KPMG USA (Audit), Arthur Andersen USA
Michael Kalafer, MD Chief Medical Officer	25	Board Certified in Pulmonary Medicine, Critical Care Medicine and Internal Medicine. Associate Clinical Professorship of Medicine at UCSD School of Medicine since 1985
Masatsuno Okajima, CMA VP, Head of Japanese Office	17	Daiwa Securities SMBC, Sumitomo Capital Securities, Sumitomo Bank

MEDICINOVA

Investment Highlights

MN-221 (Acute Exacerbations of Asthma):

- Proven mechanism of action
  - Highly selective with improved safety profile vs. standard of care
- Positive Phase IIa efficacy data
- Phase IIb study initiated by holding an Investigator's meeting in January 2009

MN-166 (Multiple Sclerosis):

- Both chronic and acute efficacy have been demonstrated in clinical studies completed to date
- MediciNova is seeking a partner to advance the clinical development of MN-166

Minimized Burn Rate:

- Annual burn rate reduced compared to previous years as a result of focus on MN-166 and MN-221 development programs
- ~$47.5M Cash, Cash Equivalents and Marketable Securities as of 9/30/08

MEDICINOVA

MEDICINOVA

Addendum:

Additional Data

MN-221-Study 6 Design

- Randomized, modified single-blind, dose escalation, placebo-controlled Phase II Study in acute asthma patients in EDs
- Approx. 36 patients in 3 dose cohorts at 8 ED clinical sites
- Doses: 16µg/min x15 (240µg)
  30µg/min x15 (450µg)
  16µg/min x15;8µg/min x105 (1,080µg)
- Patients will receive Standard of Care (SOC) treatment in addition to adjunctive treatment with MN-221 or placebo
- Safety and efficacy (FEV1 and other) data will be summarized
- No inferential statistical analysis
- Help inform design of future, larger Phase III clinical trials

MEDICINOVA

MN-221: Safety

Phase IIa Study Safety Findings:

- No clinically significant cardiovascular, ECG, or vital sign changes, or other safety concerns, observed at doses up to 30 micrograms/minute for 15 minutes or any time point thereafter
- 60 micrograms/minute infusion improved FEV1 significantly (*p< 0.0001*) without clinically significant cardiovascular, ECG or vital sign changes

Safety Database:

- MN-221 has been tested in over 300 subjects in the US and Europe to date
- Subjects have had infusions with no clinically significant adverse events at:
  - 16 micrograms/minute for up to 4 hours and at lower doses for up to 24 hours

There are substantial unmet needs in MS

	Description
Efficacy (relapse rate)	▪ Current agents offer only 30-50% relapse reduction ▪ Neutralizing antibodies can diminish efficacy over time ▪ Progression (RRMS) –neurodegeneration leads to permanent functional disability ▪ No approved treatment for PPMS, SPMS
Safety/ tolerability	▪ AEs—including flu-like symptoms ▪ SAEs –Rare, fatal PML and heptotoxicity with Tysabri ▪ Reports of significant FTY side effects (e.g. hepatotoxicity), serious or fatal opportunistic infections, skin cancer
Administration	▪ Injections – daily up to weekly ▪ Infusions -- monthly
Combination	▪ Increasing interest in combination therapies given incomplete efficacy with current “core” agents ▪ Black box on combination with Tysabri, REMS program
Neuroprotection	▪ Historically, anti-inflammatory agents have shown little impact on disease progression ▪ Demonstrated neuroprotection, that is, reduction in disease progression, would be groundbreaking

Multiple Sclerosis Market*

Approx. Sales 2007**	Compound	Sponsor	Side Effects
$3.3 Billion	**Copaxone®**	Teva& Sanofi-Aventis	Pain, redness, swelling, itching, chest pain, weakness, infection, nausea, anxiety are most common, also heart palpitations and trouble breathing after injection
$1.9 Billion	**Avonex®**	Biogen-Idec	Depression and Flu-like symptoms most common, also liver injury, severe allergic reactions, drop in red/white blood cell count
$1.7 Billion	**Rebif®**	Serono& Pfizer	Depression and Flu-like symptoms most common, also liver problems, injection site problems, severe allergic reactions, trouble breathing/loss of consciousness
$1.4 Billion	**Betaseron®**	Bayer	Lymphopenia, injection site reaction, asthenia, flu-like symptoms are most common, also necrosis at injection site
$343 Million	**Tysabri®**	Biogen-Idec	Infections, depression, pneumonia, acute hypersensitivity reactions, appendicitis most common, also liver damage, PML

All these top selling drugs for MS are immunomodulators

***Source: MedAdNews, July 2008 and BIIB annual report 2007*

MEDICINOVA

Chronic Efficacy Demonstrated: Effects on Brain Volume



Brain volume changes are linked to axonal l

MEDICINOVA

Reduction of Persistent Black Hole (PBH) Formation, a Sign of Axonal Loss

Parameter	Treatment Groups		
	Placebo	30 mg/day	60 mg/day
# Patients w. New Lesions at Month 2	72	64	56
# Patients w. ≥ 1 PBH (% of Pts. w. New Lesions)	41 (56.9%)	33 (51.6%)	28 (50%)
Mean Proportion of Lesions Evolving to PBH	0.24	0.20	0.16
Median Proportion of Lesions Evolving to PBH	0.17	0.08	0.04
Relative Risk (for Evolution to PBH) vs. placebo	-	0.74	0.63
p Value	-	0.074	**0.011**

- **New T1 gadolinium-enhancing or new T2 lesions were defined as NL in the first on-study MRI at month 2**
- **Lesions that were hypointense and inactive at month 10 were PBH**
- **Relative Risk (RR) of NL evolution to PBH was analyzed using a general linear model with the error term from the Poisson distribution**

MEDICINOVA

MN-166 Overview-Safety

- **MN-166 was very well tolerated in Phase II study:**
  - 89% (264 of 297) of subjects completed the first 12 months of the study
  - 82.5% (245 of 297) of subjects completed the full 24 months of the study
- **Discontinuation due to adverse effects was infrequent** (5.1% in 60 mg/day for 24 months, 2.1% in 30 mg/day for 24 months, 2.0% in placebo to 60 mg/day, 1.9% in placebo to 30 mg/day)
- **Adverse effects were generally mild and self-limiting**
- **GI adverse effects as a group and depression were the only adverse events to occur more frequently in MN-166-treated than in placebo-treated subjects**
- **Tolerance to the GI side effects occurred rapidly (2-4 days) and tended to occur early in treatment whether MN-166 treatment was initiated in Year 1 or Year 2**
- **Mild-to-moderate depression was reported in 8 subjects; depression is common in MS patients and was reported only towards the end of the study**
- **No significant increase in adverse laboratory or ECG findings was observed**
- **20 serious adverse events were reported; all were unlikely to be attributable to treatment**
- **No deaths occurred in the study**

MEDICINOVA

Safety Comparison with Other Oral Agents

Compound	Sponsor	Current Phase	Safety Profile from Phase II trials		
MN-166	MediciNova	Phase II	Mild, transient GI upset		
FTY 720	Novartis	Phase III	↑ Blood pressure ↓ Heart rate	Dyspnea	↑Liver enzymes Lymphopenia
Cladribine	Merck Serono	Phase III	Fever	Nausea, Vomiting	Leucopenia
BG-12	Biogen-Idec	Phase III	H/A, Nasopharyngitis	GI disorders	↑Liver enzymes
Laquinimod	Teva	Phase III	↑ Liver enzymes	Arthralgia	↑Fibrinogen ↓Hemoglobin

MEDICINOVA